[Objective functional monitoring of retinoprotective treatment in diabetic retinopathy].

Q3 Medicine

Vestnik oftalmologii Pub Date : 2024-01-01 DOI:10.17116/oftalma202414001145

A I Malakhova, V V Strakhov, Y D Kovaleva, Y A Malakhova

{"title":"[Objective functional monitoring of retinoprotective treatment in diabetic retinopathy].","authors":"A I Malakhova, V V Strakhov, Y D Kovaleva, Y A Malakhova","doi":"10.17116/oftalma202414001145","DOIUrl":null,"url":null,"abstract":"In recent years, there has been a growing interest in the contribution of neuroretinal degeneration to the pathogenesis of diabetic retinopathy (DR).Purpose: This study assesses the effect of the drug Retinalamin on the functional state of the retina in patients with DR using the Diopsys NOVA Vision Testing System that utilizes electrophysiological (EP) technology.Material and methods: The study included patients with type 1 and 2 diabetes mellitus (DM) with DR of any stage without macular edema. Patients underwent standard ophthalmological examination and objective functional examination of the retina using the Diopsys NOVA Vision Testing System. The control group consisted of patients with type 1 and 2 DM with DR who did not receive Retinalamin.Results: Significant changes in pattern electroretinography and flash electroretinography parameters were recorded in patients who received a course of Retinalamin. Two clinical examples are presented, which can be designated as the first experience of objective functional monitoring of treatment of patients with DR with Retinalamin.Conclusion: Retinoprotective therapy is necessary already at the early stages of DR. Electroretinography is an objective tool for functional analysis of the earliest changes in retinal cells in DR. It is necessary to use the identified \"therapeutic\" window for the appointment of retinoprotective agents.","PeriodicalId":23529,"journal":{"name":"Vestnik oftalmologii","volume":"140 1","pages":"45-56"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vestnik oftalmologii","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17116/oftalma202414001145","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

In recent years, there has been a growing interest in the contribution of neuroretinal degeneration to the pathogenesis of diabetic retinopathy (DR).

Purpose: This study assesses the effect of the drug Retinalamin on the functional state of the retina in patients with DR using the Diopsys NOVA Vision Testing System that utilizes electrophysiological (EP) technology.

Material and methods: The study included patients with type 1 and 2 diabetes mellitus (DM) with DR of any stage without macular edema. Patients underwent standard ophthalmological examination and objective functional examination of the retina using the Diopsys NOVA Vision Testing System. The control group consisted of patients with type 1 and 2 DM with DR who did not receive Retinalamin.

Results: Significant changes in pattern electroretinography and flash electroretinography parameters were recorded in patients who received a course of Retinalamin. Two clinical examples are presented, which can be designated as the first experience of objective functional monitoring of treatment of patients with DR with Retinalamin.

Conclusion: Retinoprotective therapy is necessary already at the early stages of DR. Electroretinography is an objective tool for functional analysis of the earliest changes in retinal cells in DR. It is necessary to use the identified "therapeutic" window for the appointment of retinoprotective agents.

查看原文本刊更多论文

[糖尿病视网膜病变视网膜保护治疗的客观功能监测]。

近年来，人们越来越关注神经视网膜变性对糖尿病视网膜病变（DR）发病机理的影响。目的：本研究使用采用电生理（EP）技术的 Diopsys NOVA 视觉测试系统，评估药物视网膜素对 DR 患者视网膜功能状态的影响：研究对象包括患有任何阶段DR且无黄斑水肿的1型和2型糖尿病（DM）患者。患者接受了标准眼科检查和使用 Diopsys NOVA 视觉测试系统进行的视网膜客观功能检查。对照组包括未接受视网膜维生素治疗的 1 型和 2 型 DM DR 患者：结果：接受视网膜维生素治疗的患者的视网膜模式图和闪光视网膜模式图参数发生了显著变化。结果：接受视网膜保护剂治疗的 DR 患者的视网膜图形电图和闪烁电图参数发生了显著变化，这两个临床病例可视为使用视网膜保护剂对 DR 患者进行客观功能监测的首次经验：结论：在 DR 的早期阶段就有必要进行视网膜保护治疗。视网膜电图是对 DR 视网膜细胞最早变化进行功能分析的客观工具。有必要利用已确定的 "治疗 "窗口期来使用视网膜保护剂。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vestnik oftalmologii Medicine-Ophthalmology

CiteScore

0.80

自引率

0.00%

发文量

129

期刊介绍： The journal publishes materials on the diagnosis and treatment of eye diseases, hygiene of vision, prevention of ophthalmic affections, history of Russian ophthalmology, organization of ophthalmological aid to the population, as well as the problems of special equipment. Original scientific articles and surveys on urgent problems of theory and practice of Russian and foreign ophthalmology are published. The journal contains book reviews on ophthalmology, information on the activities of ophthalmologists" scientific societies, chronicle of congresses and conferences.The journal is intended for ophthalmologists and scientific workers dealing with clinical problems of diseases of the eye and physiology of vision.